

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):


- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.


Capillary Electrophoresis with Laser Induce Fluorescence analysis of C2B8 and other oligosaccharides.

Before enzyme treatment.




A

After treatment with β -galactosidase.




B

After treatment with β -galactosidase and N-acetyl β -D-glucosaminidase.




C

Binding of C1q to C2B8 samples pre-bound to WIL2-S cells



09163824-103098

Comparison of CDC Bioactivity of rIgG Glycoforms



09183824-103098

3


Fig.

4

Analysis of N-linked Oligosaccharides of C2B8 by Capillary Electrophoresis

123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100

UFR




A

B

5

Fig.

Galactosylation of anti-VEGF



09183824-103098

Fig. 6





Fig. 7



09183824-103098

Fig.

8






Fig. 9




Reduced

Fig. 10
Far UV CD Spectra of C2B8 Antibody Variants



09183824-103098

Fig. 10B Near UV Spectra of C2B8 Antibody Variants



09183824-103098





Fig. 12

Correlation Of Bioactivity And Galactose Content In rituximab



09183824-103098